Almost at the same time, work by several groups of investigators on different continents has brought about changes in the way hematopoietic stem cell allo-transplants are beeing carried out for the treatment of patients with hematological diseases. Specifically, the focus has shiftetd away from attempts at eradicating malignant cells through high-dose chemoradiation therapy toward using the stem cell donor's immune cells for that purpose (allogeneic graft-versustumor effect). While most of the non-myeloablative transplant regimens used in these efforts are still fairly intense and toxic, the most radical departure from conventional transplantation focuses on the almost exclusive use of noncytotoxic immunosuppressive agents to establish allografts, and the success of the transplants rests on an allogeneic graft-versus-tumor effect induced by subsequent infusions of stem cell donor's lymphocytes. 
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There are several reports on allogeneic cell therapy after so called 'non-myeloablative conditioning regimens. 23 patients (15 unrelated/8 related) with advanced disease prior to infectious complications or reduced performance status (6 CML, 7 AML, 5 MDS, 2 ALL, 1 NHL, 2 M. Hodgkin) received 3.3 mg/kg busulfan, i.v. on days −6 and −5 (total dose 6.6 mg/kg i.v.), 30 mg/m 2 ATG from day −5 to −2 (total dose 10 mg/kg). The oldest patient was 60 at the time of the transplant. The patients received unmanipulated PBSC (n = 13), CD34+-enriched PBSC (n = 7) or unmanipulated BM (n = 3). GvHD-prophylaxis was performed with cyclosporine 3 mg/kg starting day −1. Patients transplanted with unmanipulatedgrafts received 5 mg/m 2 methetrexate on days +1, +3 and +6. Primary engraftment with predominating donor chiomerism was documented in all patients. Four patients after unrelated transplants experienced secondary graft failure which was associated with CMV antigenemia in 2 cases. Few infectious complications were observed and transfusion requirements were moderate. Acute GvHD Յ II was observed in 8 patients. Sequential analysis of chimerism in cellular subsets showed a complete T-cell chimerism to be a prerequisite for a clinical GvHD. The increase of T-cell chimerism was heterogenous and depended on underlying disease, pretreatment and performance of CD34-enrichment. After a median observation period of 120 days, 17 patients are alive and free of disease. Four patients (1 AML, 1 MDS, 1Ph+ ALL, 1 CML) have relapsed. These data suggest that lymphohematopoietic chimerism from unrelated donors can be established in patients after less intense preparative regimens. ATG may be omitted in the related setting. Since myeloablation is induced passively by the allogeneic graft, we have proposed an alternative term, 'metakine' transplantation.
